RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2
Project

First in the EU. Contract concluded for the production of Sputnik V in Italy

Customers: Russian Direct Investment Fund (RDIF)

Moscow; Financial Services, Investments and Auditing

Product: Satellite V (COVID-19 coronavirus vaccine)

Project date: 2021/03

On March 9, 2021, it became known about an agreement signed by the Russian Direct Investment Fund (RDIF) and the Swiss holding Adienne Pharma & Biotech. We are talking about the production of a vaccine for the COVID-19 Sputnik V coronavirus in Italy.

Under the terms of the contract, Adienne Pharma & Biotech the Italian Adienne Srl, a member of the holding company, will begin production of Sputnik V in June 2021. It is planned to release about 10 million doses of the drug by the end of the year.

Contract concluded between RDIF and Adienne Pharma & Biotech for production of Sputnik V in Italy

Italy will become the first country in the European Union where they will begin to produce a Russian vaccine. It is noted that Adienne Pharma & Biotech at the end of 2020 proposed to sign a strategic agreement for the local production of Sputnik V in Italy.

File:Aquote1.png
This agreement is the first of its kind with a European partner. It can be called a historical event that proves the good state of bilateral relations between our countries and shows us that Italian companies can see beyond political differences, "said Vincenzo Trani, president of the Italian-Russian Chamber of Commerce, whose words are quoted on its website.
File:Aquote2.png

According to him, Sputnik V will be produced in Italy even if the European Medicines Agency does not give approval for the use of this drug in the European Union.

RDIF CEO Kirill Dmitriev in an interview with the Italian television channel Rai3 said that the timing of the start of production of the Russian drug in Italy depends on the approval of Italian regulatory bodies.

According to Dmitriev, the production mechanism will help create new jobs and provide Italy with the opportunity to control the product.

The production of a Russian vaccine will help solve the problem of a shortage of drugs for coronavirus infection in Italy. Due to complications associated with COVID-19, by March 9, 2021, more than 100 thousand people died in the country.[1][2]

Notes